Prospective Evaluation of a Fractional 675‐nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV
Lasers in Surgery and Medicine · 2026
DOI: 10.1002/lsm.70085 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Lasers in Surgery and Medicine, 2026. Verfasst von Pinthisa Nisagornsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Cicatrix, Acne Vulgaris, Low-Level Light Therapy, Lasers, Solid-State. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Energy‐based treatments for atrophic acne scars (AAS) in darker skin phototypes must balance efficacy with pigmentary safety. While the nonablative 675‐nm laser has shown promise with minimal risk of adverse effects, prospective data in Asian populations remain limited. This study evaluated the efficacy, tolerability, and safety of a 675‐nm laser for AAS in Fitzpatrick skin types (FSTs) III–IV.
Methods
Sixteen adults with AAS underwent 3 monthly sessions using sequential Moveo (low‐fluence scanning) and Standard (fractional stamping) modes. Outcomes were assessed at baseline and at 1, 3, and 6 months after the final session, including Goodman and Baron quantitative scores (GBQGASGS), Antera® 3D imaging device, patient satisfaction, procedural pain, and adverse events.
Results
GBQGASGS improved by 14.5% at 6 months after the final treatment (19.81 ± 7.31 to 16.94 ± 7.18; p = 0.001), with a 9.7% reduction evident 1 month after the second session ( p = 0.017). Antera® 3D analysis demonstrated improvements in skin texture (12.91 ± 4.25 to 11.38 ± 3.97; p = 0.002) and scar volume (2.54 ± 1.33 to 2.04 ± 1.26; p = 0.001). At 6 months, blinded evaluators reported ≥ 25% improvement in 50% of subjects, while 69% of patients reported ≥ 25% improvement. Adverse events were of low incidence and transient in nature, and no serious complications occurred.
Conclusions
The 675‐nm laser demonstrated significant and sustained improvements in acne scar metrics in Asian patients with FST III–IV, supporting its role as a pigment‐safe, nonablative option for atrophic acne scars in skin of color. Trial Registration: Thai Clinical Trials Registry: TCTR20250218009.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Yanin Nokdhes, Jayne Bernadeth Li, Woraphong Manuskiatti
Zitieren
APA
Nisagornsen, P., Thongjaroensirikul, P., Nokdhes, Y., Bhorntarakcharoen, W., Sittiwanaruk, S., Li, J. B., & Manuskiatti, W. (2026). Prospective Evaluation of a Fractional 675‐nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV. Lasers in Surgery and Medicine. https://doi.org/10.1002/lsm.70085
Vancouver
Nisagornsen P, Thongjaroensirikul P, Nokdhes Y, Bhorntarakcharoen W, Sittiwanaruk S, Li JB, et al. Prospective Evaluation of a Fractional 675‐nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV. Lasers in Surgery and Medicine. 2026. doi:10.1002/lsm.70085
BibTeX
@article{Nisagornsen2026,
author = {Nisagornsen, Pinthisa and Thongjaroensirikul, Panwadee and Nokdhes, Yanin and Bhorntarakcharoen, Woramate and Sittiwanaruk, Sariya and Li, Jayne Bernadeth and Manuskiatti, Woraphong},
title = {Prospective Evaluation of a Fractional 675‐nm Nonablative Laser for Atrophic Acne Scars in Fitzpatrick Skin Types III–IV},
journal = {Lasers in Surgery and Medicine},
year = {2026},
doi = {10.1002/lsm.70085}
}
EUVIMED